Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Vaccine ; 41(40): 5892-5900, 2023 09 15.
Article in English | MEDLINE | ID: mdl-37599141

ABSTRACT

Zika virus infection continues to be a global concern for human health due to the high-risk association of the disease with neurological disorders and microcephaly in newborn. Nowadays, no vaccine or specific antiviral treatment is available, and the development of safe and effective vaccines is yet a challenge. In this study, we obtained a novel subunit vaccine that combines two regions of zika genome, domain III of the envelope and the capsid, in a chimeric protein in E. coli bacteria. The recombinant protein was characterized with polyclonal anti-ZIKV and anti-DENV antibodies that corroborate the specificity of the molecule. In addition, the PBMC from zika-immune donors stimulated with the ZEC recombinant antigen showed the capacity to recall the memory T cell response previously generated by the natural infection. The chimeric protein ZEC was able to self-assemble after combination with an immunomodulatory specific oligonucleotide to form aggregates. The inoculation of BALB/c mice with ZEC aggregated and not aggregated form of the protein showed a similar humoral immune response, although the aggregated variant induced more cell-mediated immunity evaluated by in vitro IFNγ secretion. In this study, we propose a novel vaccine candidate against the zika disease based on a recombinant protein that can stimulate both arms of the immune system.


Subject(s)
Zika Virus Infection , Zika Virus , Humans , Animals , Mice , Capsid , Escherichia coli , Leukocytes, Mononuclear , Capsid Proteins/genetics , Immunity, Cellular , Zika Virus Infection/prevention & control , Recombinant Proteins , Recombinant Fusion Proteins
2.
J Gen Virol ; 100(6): 975-984, 2019 06.
Article in English | MEDLINE | ID: mdl-31090533

ABSTRACT

The development of live-attenuated vaccines against Dengue virus (DENV) has been problematic. Dengvaxia, licensed in several countries where DENV is endemic, has shown low efficacy profiles and there are safety concerns prohibiting its administration to children younger than 9 years old, and the live-attenuated tetravalent vaccine (LATV) developed by NIAID has proven too reactogenic during clinical trialing. In this work we examined whether the combination of TV005, a LATV-derived formulation, with Tetra DIIIC, a subunit vaccine candidate based on fusion proteins derived from structural proteins from all four DENV serotypes, can overcome the respective limitations of these two vaccine approaches. Rhesus macaques were first primed with one or two doses of Tetra DIIIC and then boosted with TV005, following the time course of the appearance of virus-binding and neutralizing antibodies, and evaluating protection by means of a challenge experiment with wild-type viruses. Although the two evaluated prime-boost regimes were equivalent to a single administration of TV005 in terms of the development of virus-binding and neutralizing antibodies as well as the protection against viral challenge, both regimes reduced vaccine viremia to undetectable levels. Thus, the combination of Tetra DIIIC with TV005 offers a potential solution to the reactogenicity problems, which have beset the development of the latter vaccine candidate.


Subject(s)
Dengue Virus/immunology , Dengue/immunology , Recombinant Fusion Proteins/immunology , Vaccines, Attenuated/immunology , Animals , Antibodies, Neutralizing/immunology , Cell Line , Chlorocebus aethiops , Dengue/virology , Female , Immunization/methods , Immunization, Secondary/methods , Macaca mulatta , Male , Vero Cells
3.
Clin Transl Immunology ; 6(6): e148, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28748091

ABSTRACT

Tetra DIIIC is a vaccine candidate against dengue virus (DENV) composed by four chimeric proteins that fuse the domain III of the envelope protein of each virus to the corresponding capsid protein. Containing B- and T-cell epitopes, these proteins form aggregates after the incubation with an immunostimulatory oligodeoxynucleotide, and their tetravalent formulation induces neutralizing antibodies and cellular immune response in mice and monkeys. Also, Tetra DIIIC protects mice after challenge with each DENV, and the monovalent formulation obtained from DENV-2 protects monkeys upon homologous viral challenge. However, in the last years, new evidences have arisen regarding domain III of DENV envelope protein as irrelevant target for neutralizing antibodies in humans. Nevertheless, vaccination with domain III induces a neutralizing antibody response that confers protection against re-infection. In addition, it has been demonstrated that the induction of a cellular immune response is essential to protect during the infection. This response can also avoid severe manifestations of dengue disease, associated to the antibody-dependent enhancement of the infection. In this study, we observed that Tetra DIIIC was able to boost the antiviral and neutralizing antibody responses previously generated in monkeys during an experimental DENV infection, demonstrating that domain III is targeted by B cells during the viral infection. Additionally, Tetra DIIIC successfully boosted the cellular immune response generated by the viruses, probably against T-cells epitopes in the capsid proteins. These results highlight the functionality of Tetra DIIIC as a vaccine candidate against DENV.

4.
Arch Virol ; 162(8): 2247-2256, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28393307

ABSTRACT

Tetra DIIIC is a subunit vaccine candidate based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. This vaccine preparation contains the DIIIC proteins aggregated with a specific immunostimulatory oligodeoxynucleotide (ODN 39M). Tetra DIIIC has already been shown to be immunogenic and protective in mice and monkeys. In this study, we evaluated the immunogenicity in mice of several formulations of Tetra DIIIC containing different amounts of the recombinant proteins. The Tetra DIIIC formulation induced a humoral immune response against the four DENV serotypes, even at the lowest dose assayed. In contrast, the highest level of cell-mediated immunity, measured as frequency of IFNγ-producing cells, was detected in animals immunized with the lowest dose. The protective capacity of the tetravalent formulations was assessed using the mouse model of dengue virus encephalitis. Upon challenge, vaccinated mice showed significantly reduced virus replication in all tested groups. This study provides new information about the functionality of Tetra DIIIC as a vaccine candidate and also supports the crucial role of cell-mediated immunity in protection against dengue virus.


Subject(s)
Antibodies, Viral/blood , Capsid Proteins/immunology , Dengue Vaccines/immunology , Dengue/prevention & control , Immunity, Humoral , Animals , Antibodies, Neutralizing/blood , Brain/virology , Capsid Proteins/genetics , Chlorocebus aethiops , Dengue Virus , Disease Models, Animal , Dose-Response Relationship, Immunologic , Female , Immunity, Cellular , Mice , Mice, Inbred BALB C , Recombinant Proteins/immunology , Vaccines, Subunit/immunology , Vero Cells , Viremia
5.
J Immunol ; 197(9): 3597-3606, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27683751

ABSTRACT

Despite the considerable effort that has been invested in elucidating the mechanisms of protection and immunopathogenesis associated with dengue virus infections, a reliable correlate of protection against the disease remains to be found. Neutralizing Abs, long considered the prime component of a protective response, can exacerbate disease severity when present at subprotective levels, and a growing body of data is challenging the notion that their titers are positively correlated with disease protection. Consequently, the protective role of cell-mediated immunity in the control of dengue infections has begun to be studied. Although earlier research implicated cellular immunity in dengue immunopathogenesis, a wealth of newer data demonstrated that multifunctional CD8+ T cell responses are instrumental for avoiding the more severe manifestations of dengue disease. In this article, we describe a new tetravalent vaccine candidate based on recombinant dengue virus capsid proteins, efficiently produced in Escherichia coli and purified using a single ion-exchange chromatography step. After aggregation to form nucleocapsid-like particles upon incubation with an oligodeoxynucleotide containing immunostimulatory CpG motifs, these Ags induce, in mice and monkeys, an IFN-γ-secreting cell response that significantly reduces viral load after challenge without the contribution of antiviral Abs. Therefore, this new vaccine candidate may not carry the risk for disease enhancement associated with Ab-based formulations.


Subject(s)
Antibodies, Neutralizing/immunology , CD8-Positive T-Lymphocytes/immunology , Dengue Virus/physiology , Dengue/immunology , Interferon-gamma/metabolism , Viral Vaccines/immunology , Virion/immunology , Animals , CD8-Positive T-Lymphocytes/virology , Disease Models, Animal , Haplorhini , Humans , Immunity, Cellular , Mice , Nucleocapsid Proteins/immunology , Viral Load
6.
Int J Med Microbiol ; 301(1): 16-25, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20708963

ABSTRACT

Neisseria meningitidis causes meningitis and septicemia. There is no single vaccine against all serogroup B meningococcal (MenB) strains up to now. Their capsular polysaccharide (MenB CPS) bears epitopes both cross-reacting and non-cross-reactive with human polysialic acid. A bactericidal and protective antibody mAb (13D9) recognizing a unique epitope in MenB CPS was used to screen a phage-displayed peptide library. Four peptides, able to bind mAb 13D9 in competition with MenB CPS, were identified. Immunization of mice with the phage-displayed peptides elicited anti-peptide IgG antibodies, mainly IgG(2a) for 3 of the peptides and bactericidal and protective antibody levels for one of them. Peptides specifically targeting the immune response toward epitopes found only in MenB CPS could be considered for a universal vaccine against serogroup B meningococcal strains.


Subject(s)
Meningococcal Vaccines/immunology , Neisseria meningitidis/immunology , Peptides/immunology , Polysaccharides, Bacterial/immunology , Animals , Antibodies, Bacterial/blood , Female , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Microbial Viability , Peptide Library , Rats , Serum Bactericidal Antibody Assay
7.
Vaccine ; 28(2): 532-41, 2009 Dec 11.
Article in English | MEDLINE | ID: mdl-19837092

ABSTRACT

The difficulty of inducing an effective immune response against the Neisseria meningitidis serogroup B capsular polysaccharide has lead to the search for vaccines for this serogroup based on outer membrane proteins. The availability of the first meningococcal genome (MC58 strain) allowed the expansion of high-throughput methods to explore the protein profile displayed by N. meningitidis. By combining a pan-genome analysis with an extensive experimental validation to identify new potential vaccine candidates, genes coding for antigens likely to be exposed on the surface of the meningococcus were selected after a multistep comparative analysis of entire Neisseria genomes. Eleven novel putative ORF annotations were reported for serogroup B strain MC58. Furthermore, a total of 20 new predicted potential pan-neisserial vaccine candidates were produced as recombinant proteins and evaluated using immunological assays. Potential vaccine candidate coding genes were PCR-amplified from a panel of representative strains and their variability analyzed using maximum likelihood approaches for detecting positive selection. Finally, five proteins all capable of inducing a functional antibody response vs N. meningitidis strain CU385 were identified as new attractive vaccine candidates: NMB0606 a potential YajC orthologue, NMB0928 the neisserial NlpB (BamC), NMB0873 a LolB orthologue, NMB1163 a protein belonging to a curli-like assembly machinery, and NMB0938 (a neisserial specific antigen) with evidence of positive selection appreciated for NMB0928. The new set of vaccine candidates and the novel proposed functions will open a new wave of research in the search for the elusive neisserial vaccine.


Subject(s)
Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Genome, Bacterial/genetics , Meningococcal Vaccines/immunology , Neisseria meningitidis, Serogroup B/genetics , Neisseria meningitidis, Serogroup B/immunology , Animals , Animals, Newborn , Computational Biology , Enzyme-Linked Immunosorbent Assay , Meningococcal Vaccines/genetics , Mice , Mice, Inbred BALB C , Polymerase Chain Reaction , Rats
8.
Vaccine ; 27(49): 6910-7, 2009 Nov 16.
Article in English | MEDLINE | ID: mdl-19751688

ABSTRACT

The availability of complete genome sequence of Neisseria meningitidis serogroup B strain MC58 and reverse vaccinology has allowed the discovery of several novel antigens. Here, we have explored the potential of N. meningitidis lipoprotein NMB0938 as a vaccine candidate, based on investigation of gene sequence conservation and the antibody response elicited after immunization in mice. This antigen was previously identified by a genome-based approach as an outer membrane lipoprotein unique to the Neisseria genus. The nmb0938 gene was present in all 37 Neisseria isolates analyzed in this study. Based on amino acid sequence identity, 16 unique sequences were identified which clustered into three variants with identities ranging from 92 to 99%, with one cluster represented by the Neisseria lactamica strains. Recombinant protein NMB0938 (rNMB0938) was expressed in Escherichia coli and purified after solubilization of the insoluble fraction. Antisera produced in mice against purified rNMB0938 reacted with a range of meningococcal strains in whole-cell ELISA and western blotting. Using flow cytometry, it was also shown that anti-rNMB0938 antibodies bound to the surface of the homologous meningococcal strain and activated complement deposition. Moreover, antibodies against rNMB0938 elicited complement-mediated killing of meningococcal strains from both sequence variants and conferred passive protection against meningococcal bacteremia in infant rats. According to our results, NMB0938 represents a promising candidate to be included in a vaccine to prevent meningococcal disease.


Subject(s)
Antibodies, Bacterial/immunology , Antigens, Bacterial/immunology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/immunology , Amino Acid Sequence , Animals , Antibodies, Bacterial/blood , Bacterial Outer Membrane Proteins/immunology , Blotting, Western , Complement System Proteins/immunology , Computational Biology , DNA, Bacterial/genetics , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Meningococcal Infections/immunology , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Neisseria meningitidis, Serogroup B/genetics , Neisseria meningitidis, Serogroup B/immunology , Phylogeny , Rats , Recombinant Proteins/immunology , Sequence Alignment
9.
J Med Microbiol ; 58(Pt 2): 196-208, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19141737

ABSTRACT

The significance of Neisseria meningitidis serogroup B membrane proteins as vaccine candidates is continually growing. Here, we studied different aspects of antigen NMB0088, a protein that is abundant in outer-membrane vesicle preparations and is thought to be a surface protein. The gene encoding protein NMB0088 was sequenced in a panel of 34 different meningococcal strains with clinical and epidemiological relevance. After this analysis, four variants of NMB0088 were identified; the variability was confined to three specific segments, designated VR1, VR2 and VR3. Secondary structure predictions, refined with alignment analysis and homology modelling using FadL of Escherichia coli, revealed that almost all the variable regions were located in extracellular loop domains. In addition, the NMB0088 antigen was expressed in E. coli and a procedure for obtaining purified recombinant NMB0088 is described. The humoral immune response elicited in BALB/c mice was measured by ELISA and Western blotting, while the functional activity of these antibodies was determined in a serum bactericidal assay and an animal protection model. After immunization in mice, the recombinant protein was capable of inducing a protective response when it was administered inserted into liposomes. According to our results, the recombinant NMB0088 protein may represent a novel antigen for a vaccine against meningococcal disease. However, results from the variability study should be considered for designing a cross-protective formulation in future studies.


Subject(s)
Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Meningococcal Vaccines/immunology , Neisseria meningitidis/genetics , Neisseria meningitidis/immunology , Polymorphism, Genetic/immunology , Amino Acid Sequence , Animals , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Antigens, Bacterial/analysis , Bacterial Outer Membrane Proteins/analysis , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/immunology , Blotting, Western , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Enzyme-Linked Immunosorbent Assay/methods , Escherichia coli/genetics , Female , Gene Expression , Humans , Meningococcal Infections/microbiology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/genetics , Mice , Mice, Inbred BALB C , Microbial Viability , Molecular Sequence Data , Neisseria meningitidis/chemistry , Neisseria meningitidis/isolation & purification , Protein Structure, Secondary , Rats , Sequence Alignment , Sequence Analysis, DNA
10.
J Med Microbiol ; 582009. tab
Article in English | CUMED | ID: cum-44533

ABSTRACT

The significance of Neisseria meningitidis serogroup B membrane proteins as vaccine candidates is continually growing. Here, we studied different aspects of antigen NMB0088, a protein that is abundant in outer-membrane vesicle preparations and is thought to be a surface protein. The gene encoding protein NMB0088 was sequenced in a panel of 34 different meningococcal strains with clinical and epidemiological relevance. After this analysis, four variants of NMB0088 were identified; the variability was confined to three specific segments, designated VR1, VR2 and VR3. Secondary structure predictions, refined with alignment analysis and homology modelling using FadL of Escherichia coli, revealed that almost all the variable regions were located in extracellular loop domains. In addition, the NMB0088 antigen was expressed in E. coli and a procedure for obtaining purified recombinant NMB0088 is described. The humoral immune response elicited in BALB/c mice was measured by ELISA and Western blotting, while the functional activity of these antibodies was determined in a serum bactericidal assay and an animal protection model. After immunization in mice, the recombinant protein was capable of inducing a protective response when it was administered inserted into liposomes. According to our results, the recombinant NMB0088 protein may represent a novel antigen for a vaccine against meningococcal disease. However, results from the variability study should be considered for designing a cross-protective formulation in future studies(AU)


Subject(s)
Animals , Mice , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Meningococcal Vaccines/immunology , Neisseria meningitidis/immunology , Neisseria meningitidis/isolation & purification , Polymorphism, Genetic/immunology
11.
Vaccine ; 25(50): 8420-31, 2007 Dec 05.
Article in English | MEDLINE | ID: mdl-17996338

ABSTRACT

Polysaccharide-based vaccines for serogroup B Neisseria meningitidis have failed to induce protective immunity. As a result, efforts to develop vaccines for serogroup B meningococcal disease have mostly focused on outer membrane proteins (OMP). Vaccine candidates based on meningococcal OMP have emerged in the form of outer membrane vesicles (OMVs) or, more recently, purified recombinant proteins, as alternative strategies for serogroup B vaccine development. In our group, the protein composition of the Cuban OMVs-based vaccine VA-MENGOC-BC was elucidated using two-dimensional gel electrophoresis and mass spectrometry. The proteomic map of this product allowed the identification of new putative protective proteins not previously reported as components of an antimeningococcal vaccine. In the present study, we have determined the immunogenicity and protective capacity of NMB0928, one of those proteins present in the OMVs. The antigen was obtained as a recombinant protein in Escherichia coli, purified and used to immunize mice. The antiserum produced against the protein was capable to recognize the natural protein in different meningococcal strains by whole-cell ELISA and Western blotting. After immunization, recombinant NMB0928 induced bactericidal antibodies, and when the protein was administered inserted into liposomes, the elicited antibodies were protective in the infant rat model. These results suggest that NMB0928 is a novel antigen worth to be included in a broadly protective meningococcal vaccine.


Subject(s)
Lipoproteins , Meningococcal Infections/prevention & control , Meningococcal Vaccines , Neisseria meningitidis, Serogroup B/immunology , Amino Acid Sequence , Animals , Animals, Newborn , Antibodies, Bacterial/blood , Bacterial Outer Membrane Proteins/chemistry , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/immunology , Bacterial Outer Membrane Proteins/metabolism , Base Sequence , Humans , Immune Sera/administration & dosage , Immune Sera/immunology , Immunization , Immunization, Passive , Lipoproteins/chemistry , Lipoproteins/genetics , Lipoproteins/immunology , Lipoproteins/metabolism , Liposomes/administration & dosage , Liposomes/immunology , Meningococcal Infections/immunology , Meningococcal Vaccines/administration & dosage , Meningococcal Vaccines/immunology , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Rats , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/metabolism , Sequence Analysis, DNA
12.
Vaccine ; 25(28): 5175-88, 2007 Jul 09.
Article in English | MEDLINE | ID: mdl-17544180

ABSTRACT

We have shown previously that expression library immunization is viable alternative approach to induce protective immunity against Neisseria meningitidis serogroup B. In this study we report that few rounds of library screening allow identification of protective pools of defined antigens. A previously reported protective meningococcal library (L8, with 600 clones) was screened and two sub-libraries of 95 clones each were selected based on the induction of bactericidal and protective antibodies in BALB/c mice. After sequence analysis of each clone within these sub-libraries, we identified a pool of 20 individual antigens that induced protective immune responses in mice against N. meningitidis infection, and the observed protection was associated with the induction of bactericidal antibodies. Our studies demonstrate for the first time that ELI combined with sequence analysis is a powerful and efficient tool for identification of candidate antigens for use in a meningococcal vaccine.


Subject(s)
Meningococcal Infections/immunology , Meningococcal Vaccines/immunology , Neisseria meningitidis, Serogroup B/immunology , Vaccines, DNA/immunology , Animals , Animals, Newborn , Bacteremia/immunology , Bacteremia/prevention & control , Blotting, Western , DNA, Bacterial/genetics , DNA, Bacterial/immunology , Enzyme-Linked Immunosorbent Assay , Genomic Library , Immune Sera/administration & dosage , Immune Sera/immunology , Male , Meningococcal Infections/prevention & control , Meningococcal Vaccines/administration & dosage , Mice , Mice, Inbred BALB C , Microbial Viability/drug effects , Neisseria meningitidis, Serogroup B/drug effects , Neisseria meningitidis, Serogroup B/genetics , Plasmids/genetics , Rats , Survival Analysis , Vaccination/methods , Vaccines, DNA/administration & dosage
13.
FEMS Immunol Med Microbiol ; 50(3): 430-3, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17537176

ABSTRACT

We employed a prime-boost regimen in combination with the expression library immunization protocol to improve the protective effectiveness of a genomic library used as immunogen. To demonstrate the feasibility of this novel strategy, we used as a prime a serogroup B Neisseria meningitidis random genomic library constructed in a eukaryotic expression vector. Mice immunized with different fractions of this library and boosted with a single dose of meningococcal outer membrane vesicles elicited higher bactericidal antibody titers compared with mice primed with the empty vector. After the boost, passive administration of sera from mice primed with two of these fractions significantly reduced the number of viable bacteria in the blood of infant rats challenged with live N. meningitidis. The method proposed could be applied to the identification of subimmunogenic antigens during vaccine candidate screening by employing expression library immunization.


Subject(s)
Antigens, Bacterial/isolation & purification , Bacterial Vaccines/isolation & purification , Genomic Library , Animals , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Bacterial Vaccines/genetics , Bacterial Vaccines/immunology , Immunization , Meningococcal Infections/blood , Meningococcal Infections/prevention & control , Mice , Neisseria meningitidis/genetics , Neisseria meningitidis/immunology , Rats , Serum/immunology
14.
Biotechnol Appl Biochem ; 44(Pt 1): 27-34, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16396627

ABSTRACT

In the post-genomic era, every aspect of the production of proteins must be accelerated. In this way, several vectors are currently exploited for rapid production of recombinant proteins in Escherichia coli. N-terminal fusions to the first 47 amino acids of the LpdA (dihydrolipoamide dehydrogenase A) protein of Neisseria meningitidis have been shown to increase the expression of recombinant proteins. Consequently, we have constructed a modified N-terminal LpdA fusion vector, introducing the blue/white colony selection by exploiting a bicistronic gene organization. In the new vector, the sequence encoding the first 47 amino acids of meningococcal LpdA and the alpha-peptide sequence of beta-galactosidase were connected via a ribosome-binding site, and two MCSs (multiple cloning sites) were located surrounding the latter, allowing efficient cloning by colour selection of recombinants. The vector was also improved with the addition of a C-terminal polyhistidine tag, and an EKS (enterokinase recognition sequence) immediately after the LpdA fusion sequence. The new plasmid was employed in the expression and purification of six different bacterial polypeptides. One of these recombinant proteins, P6 protein from Haemophilus influenzae, was used as a model and its N-terminal fusion sequence was totally removed from the recombinant version after incubation with the enterokinase protease, while the polyhistidine tail successfully allowed the purification of the unfused protein from the protease reaction. Two completely new neisserial vaccine candidates, NMB0088 and NMB1126 proteins, were cloned, expressed and purified using this system. To our knowledge, this constitutes the first report of the cloning and expression of these proteins in E. coli.


Subject(s)
Escherichia coli/genetics , Plasmids , Recombinant Fusion Proteins/biosynthesis , Amino Acid Sequence , Base Sequence , Blotting, Western , Cloning, Molecular , DNA, Recombinant , Electrophoresis, Polyacrylamide Gel , Molecular Sequence Data , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics
15.
Vaccine ; 24(10): 1633-43, 2006 Mar 06.
Article in English | MEDLINE | ID: mdl-16257096

ABSTRACT

Although vaccines based on outer membrane vesicles (OMV) of Neisseria meningitidis have been developed and administered to children, little is known about the magnitude and quality of the immune response in animal models of early life immunization. We investigated the immunogenicity of meningococcal OMV, and the influence of route and immunization schedule, in neonatal mice. The administration of two intraperitoneal doses of OMV, given at 7 and 14 days after birth, induced a significant antibody response and was highly effective in conferring protection against bacteremia in 21-day-old mice challenged with meningococci. Intranasal immunization was less effective and did not generate a protective immune response. The antibodies elicited by intraperitoneal immunization were cross-reactive with several meningococcal strains and a memory response was demonstrated when mice immunized as neonates were given a booster immunization at 6 weeks of age.


Subject(s)
Bacteremia/prevention & control , Bacterial Outer Membrane Proteins/immunology , Meningococcal Infections/prevention & control , Meningococcal Vaccines/immunology , Administration, Intranasal , Animals , Animals, Newborn , Antibodies, Bacterial/blood , Cross Reactions , Female , Immunization , Injections, Intraperitoneal , Meningococcal Vaccines/administration & dosage , Mice , Mice, Inbred BALB C
SELECTION OF CITATIONS
SEARCH DETAIL
...